NASDAQ:CORTCorcept Therapeutics Stock Price, Forecast & News

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CORT shares have increased by 50.7% and is now trading at $16.50. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corcept Therapeutics.

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corcept Therapeutics.

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.03. The biotechnology company earned $93.25 million during the quarter, compared to analyst estimates of $87.01 million. Corcept Therapeutics had a return on equity of 30.00% and a net margin of 31.64%. The business's revenue was up 43.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. View Corcept Therapeutics' earnings history.

Corcept Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Monday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $363.79 million.

3 analysts have issued 1-year price objectives for Corcept Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Corcept Therapeutics' stock price to reach $17.67 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View analysts' price targets for Corcept Therapeutics.

Headlines about CORT stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Corcept Therapeutics.

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), CA (CA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BlackRock (BLK), AbbVie (ABBV), Netflix (NFLX), Energy Transfer LP Unit (ET) and Johnson & Johnson (JNJ).

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View institutional ownership trends for Corcept Therapeutics.

CORT stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $16.50.

Corcept Therapeutics has a market capitalization of $1.89 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

The official website for Corcept Therapeutics is www.corcept.com.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]